Clinical benefits as endpoints in advanced non-small cell lung cancer treated with integrative medicine

Dong Xue; Ping-ping Li

doi:10.1007/s11655-011-0672-8

Your Location：

Home >

Browse articles >

Clinical benefits as endpoints in advanced non-small cell lung cancer treated with integrative medicine

OriginalPaper | Updated：2021-08-27

- Clinical benefits as endpoints in advanced non-small cell lung cancer treated with integrative medicine
- Clinical benefits as endpoints in advanced non-small cell lung cancer treated with integrative medicine
- 中国结合医学杂志（英文版） 2011年17卷第3期页码：228-231
- Affiliations：
  
  Department of Integrative Medicine, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Cancer Etiology, Peking University Cancer Hospital and Institute,Beijing,China
- Author bio：
- Funds：
- DOI：10.1007/s11655-011-0672-8
  中图分类号：
- 纸质出版日期：2011，
  
  网络出版日期：2011-2-27，
Scan for full text
Xue, D., Li, Pp. Clinical benefits as endpoints in advanced non-small cell lung cancer treated with integrative medicine., Chin. J. Integr. Med. 17, 228–231 (2011). https://doi.org/10.1007/s11655-011-0672-8

Dong Xue, Ping-ping Li. Clinical benefits as endpoints in advanced non-small cell lung cancer treated with integrative medicine[J]. Chinese Journal of Integrative Medicine, 2011,17(3):228-231.
Xue, D., Li, Pp. Clinical benefits as endpoints in advanced non-small cell lung cancer treated with integrative medicine., Chin. J. Integr. Med. 17, 228–231 (2011). https://doi.org/10.1007/s11655-011-0672-8 DOI：

Dong Xue, Ping-ping Li. Clinical benefits as endpoints in advanced non-small cell lung cancer treated with integrative medicine[J]. Chinese Journal of Integrative Medicine, 2011,17(3):228-231. DOI： 10.1007/s11655-011-0672-8.

摘要

“Living with cancer” and symptom control are the features and advantages of integrative medicine in advanced non-small cell lung cancer (NSCLC) treatment. However

with the current concept of response evaluation criteria by the WHO and RECIST

it is difficult to exhibit the above characteristics. Clinical benefit (CB) is designed as an endpoint recently widely understood and accepted in oncology clinical trials. With the review of its definition and development

we suggest CB to be used as an endpoint in advanced NSCLC treatment with integrative medicine. CB should encompass two connotations: one is improved quality of life and symptom control and the other is disease control rate (DCR)

including complete response (CR)

partial response (PR)

and stable disease (SD). We need to design randomized controlled trials (RCT) to investigate the interrelationship of CB rate and survival to provide high-grade evidence proving that advanced lung cancer patients could really benefit from integrative medicine treatment.

Abstract

“Living with cancer” and symptom control are the features and advantages of integrative medicine in advanced non-small cell lung cancer (NSCLC) treatment. However

with the current concept of response evaluation criteria by the WHO and RECIST

including complete response (CR)

partial response (PR)

关键词

non-small cell lung cancerChinese Medicineendpointsclinical benefit

Keywords

non-small cell lung cancerChinese Medicineendpointsclinical benefit

references

http://seer.cancer.gov/statfacts/html/lungb.html, web accessed on Nov.1st 2010.

http://www.moh.gov.cn, China Health Annual Book, 2010, web accessed on November 11st 2010.

The NCCN Clinical Practice Guidelines in Oncology (NCCN Guideline™). Non-Small Cell Lung Cancer (Chinese Version 1. 2007). © 2007 National Comprehensive Cancer Network, Inc. Available at: http://www.nccn-asia.org/cn/. 2010.

Sun Y, Lin HS, Zhu YZ, Feng JF, Chen ZT, Li GS, et al. A randomized, prospective, multi-centre clinical trial of NP regimen (vinorelbine + cisplatin) plus Gensing Rg3 in the treatment of advanced non-small cell lung cancer patients. Chin J Lung Cancer (Chin) 2006;9:254–258.

Chen S, Flower A, Ritchie A, Liu J, Molassiotis A, Yu H, et al. Oral Chinese herbal medicine (CHM) as an adjuvant treatment during chemotherapy for non-small cell lung cancer: A systematic review. Lung Cancer 2010;68:137–145.

Deng HB. Research of effect evaluation of traditional Chinese medicine in advanced non-small cell lung cancer treatment. Liaoning J Tradit Chin Med (Chin) 2003;30:815–816.

Zhou DH, Lin LZ, Tao ZG. Traditional Chinese medical oncologic evaluation system of response to treatment (TCMOES) in advanced non-small cell lung cancer. China Cancer (Chin) 2005;10:654–657.

Liu JX. Research thought and clinical experience in treatment of lung cancer with Chinese medicine. World Chin Med (Chin) 2007;2:67–70.

Lin HS, Li SQ, Piao BK. Effect evaluation of traditional Chinese medicine in advanced lung cancer treatment. China Cancer (Chin) 2000;9:354–355.

Li PP. Could we use clinical benefit to evaluate the effects of Chinese medicine on the treatment of cancer? Chin J Integr Med 2010;16:9–10.

Guidance for Industry Clinical Trial Endpoints for the Approval of Cancer Drugs and Biologics, U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) Center for Biologics Evaluation and Research (CBER), 2007 May.

Guideline on the Evaluation of Anticancer Medicinal Products in Man. European Medicines Agency Evaluation of Medicines for Human Use. http://www.ema.europa.eu/. 2010.

Rothenberg ML, Moore MJ, Cripps MC, Andersen JS, Portenoy RK, Burris HA, et al. A phase II trial of gemcitabine in patients with 5-FU-refractory pancreas cancer. Ann Oncol 1996;7:347–353.

Burris HA 3rd, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 1997;15(6):2403–2413.

Ohorodnyk P, Eisenhauer EA, Booth CM. Clinical benefit in oncology trials: Is this a patient-centred or tumour-centred end-point? Eur J Cancer 45:2249–2252.

Scheele J, Niazi F, Drevs J, Diergarten K, Toure P. A pilot study of Auron Misheil Therapy in patients with advanced cervical cancer: tumor response and its correlation with clinical benefit response, and preliminary quality of life data. Oncol Rep 2009;22:877–883.

Perey L, Paridaens R, Hawle H, Zaman K, Nole F, Wildiers H, et al. Clinical benefit of fulvestrant in postmenopausal women with advanced breast cancer and primary or acquired resistance to aromatase inhibitors: final results of phase II Swiss Group for Clinical Cancer Research Trial (SAKK 21/00). Ann Oncol 2007;18:64–69.

Al-Batran SE, Bischoff J, von Minckwitz G, A Atmaca, U Kleeberg, I Meuthen, et al. The clinical benefit of pegylated liposomal doxorubicin in patients with metastatic breast cancer previously treated with conventional anthracyclines: a multicentre phase II trial. Br J Cancer 2006; 94:1615–1920.

Lara PN Jr, Redman MW, Kelly K, Edelman MJ, Williamson SK, Crowley JJ, et al. Disease control rate at 8 weeks predicts clinical benefit in advanced non-small-cell lung cancer: results from Southwest Oncology Group randomized trials. J Clin Oncol 2008;26:463–467.

Scagliotti G, Novello S, von Pawel J, Reck M, Pereira JR, Thomas M, et al. Phase III study of carboplatin and paclitaxel alone or with sorafenib in advanced non-smallcell lung cancer. J Clin Oncol 2010;28:1835–1842.

Felip E, Rojo F, Reck M, Heller A, Klughammer B, Sala G, et al. A phase II pharmacodynamic study of erlotinib in patients with advanced non-small cell lung cancer previously treated with platinum-based chemotherapy. Clin Cancer Res 2008;14:3867–3874.

Blakely LJ, Schwartzberg L, Keaton M, Schnell F, Henry D, Epperson A, et al. A phase II trial of pemetrexed and gemcitabine as first line therapy for poor performance status and/or elderly patients with stage IIIB/IV non-small cell lung cancer. Lung Cancer 2009;66:97–102.

Reck M, von Pawel J, Zatloukal P, Ramlau R, Gorbounova V, Hirsh V, et al. Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil. J Clin Oncol 2009;27:1227–1234.

Kiura K, Nakagawa K, Shinkai T, Eguchi K, Ohe Y, Yamamoto N, et al. A randomized, double-blind, phase IIa dose-finding study of Vandetanib (ZD6474) in Japanese patients with non-small cell lung cancer. J Thorac Oncol 2008;3:386–393.

Polyzos A. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma and various other solid tumors. J Steroid Biochem Mol Biol 2008;108:261–266.

Scagliotti GV, Park K, Patil S, Rolski J, Goksel T, Martins R, et al. Survival without toxicity for cisplatin plus pemetrexed versus cisplatin plus gemcitabine in chemonaïve patients with advanced non-small cell lung cancer: a riskbenefit analysis of a large phase III study. Eur J Cancer 2009;45:2298–2303.

Fidias PM, Dakhil SR, Lyss AP, Loesch DM, Waterhouse DM, Bromund JL, et al. Phase III study of immediate compared with delayed docetaxel after front-line therapy with gemcitabine plus carboplatin in advanced non-small-cell lung cancer. J Clin Oncol 2009;27:591–598.

Dudek AZ, Larson T, McCleod MJ, Schneider DJ, Dowell JE, Banerjee TK, et al. Phase 1/2 dose escalating study of twice-monthly pemetrexed and gemcitabine in patients with advanced cancer and non-small cell lung cancer. J Thorac Oncol 2008;3:394–399.

Kosmidis PA, Dimopoulos MA, Syrigos K, Nicolaides C, Aravantinos G, Boukovinas I, et al. Gemcitabine versus gemcitabine-carboplatin for patients with advanced non-small cell lung cancer and a performance status of 2: a prospective randomized phase II study of the Hellenic Cooperative Oncology Group. J Thorac Oncol 2007;2:135–140.

Fujiwara T, Tanaka N, Kanazawa S, Ohtani S, Saijo Y, Nukiwa T, et al. Multicenter phase I study of repeated intratumoral delivery of adenoviral p53 in patients with advanced non-small-cell lung cancer. J Clin Oncol 2006;24:1689–1699.

Recchia F, Saggio G, Nuzzo A, Biondi E, Di Blasio A, Cesta A, et al. Multi-center phase 2 study of interleukin-2 and 13-cis retinoic acid as maintenance therapy in advanced non-small-cell lung cancer. J Immunother 2006;29:87–94.

Lin HS, Fan HT. Current concept and problems of nonsmall cell lung cancer treatment with traditional Chinese medicine. Chin J Sur Integr Tradit West Med (Chin) 2007;13:507–509.

Chu DT. Consensus and edification of the effect evaluation criteria in cancer treatment with integrative medicine. China Prescription Drug (Chin) 2004;29(8):42–44.

FULL TEXT LINK

More>

浏览量

622

Downloads

CSCD

文章被引用时，请邮件提醒。

Submit

工具集

关联资源

Clinical study on long-term overall survival of advanced non-small-cell lung cancer patients treated with Chinese medicine and western medicine

Effect of Feitai Capsule (肺泰胶囊) on quality of life and progression-free survival of patients with unresectable non-small cell lung cancer

In Vitro and In Vivo inhibitory effect of the combination of Wenxia Changfu Formula (温下肠腑方) with cisplatin in non-small cell lung cancer

Shenyi Capsule (参一胶囊) plus Chemotherapy versus Chemotherapy for Non-Small Cell Lung Cancer: A Systematic Review of Overlapping Meta-Analyses

Gefitinib plus Fuzheng Kang’ai Formula (扶正抗癌方) in Patients with Advanced Non-Small Cell Lung Cancer with Epidermal Growth Factor Receptor Mutation: A Randomized Controlled Trial